RESUMEN
BACKGROUND: Aelurostrongylus abstrusus is one of the most important respiratory nematodes of felines. Infections may lead to respiratory clinical signs with varying severity or even death, emphasizing the need for preventive treatment of cats with outdoor access to circumvent patent infections. METHODS: Therefore, the preventive efficacy of a spot-on formulation of 280 mg/ml fluralaner and 14 mg/ml moxidectin (Bravecto® Plus spot-on solution for cats, MSD) against A. abstrusus was evaluated in a negative controlled, randomized and partially blinded efficacy study with 28 purpose-bred cats in a non-terminal design. In three different treatment regimes, the minimum recommended dose of 40 mg fluralaner and 2.0 mg moxidectin/kg bodyweight (BW) was administered once at 12, 8 or 4 weeks (study group G1, G2 and G3, respectively) prior to experimental infection with 300 third-stage A. abstrusus larvae, while G4 served as placebo-treated control. RESULTS: From 30 to 46 days post infection (dpi; SD 114 to 130), faeces were sampled to monitor first-stage larvae (L1) excretion for efficacy determination. Secondary efficacy criteria, including respiratory parameters, serological antibody levels and computed tomography (CT) findings, were assessed once before enrolment (SD -7 to -1) and before infection (SD 75 to 83). After infection, CT evaluation was performed once at 47-50 dpi (SD 131 to 134), and respiratory parameters and antibody levels were regularly assessed twice or once a week, respectively (1 up to 78 dpi, SD 85 up to 162). All animals in the control group excreted L1 by 33-37 dpi and remained positive throughout the study period from 41 to 46 dpi (SD 125 to 130). In the treatment groups, only one animal each of G1 and G2 excreted L1 at two consecutive days, and four cats of G1, two of G2 and three of G3 were positive on single occasions. While the geometric mean (GM) of the maximum number of excreted L1 per 5 g of faeces was 7380.89 in the control group (G4), GMs were significantly lower in the treatment groups with 1.63 in G1, 1.37 in G2 and 0.79 in G3. Thus, based on GMs, the reduction in excreted L1 exceeded 99.9% in all three treatment groups. Based on CT severity scores, all lungs of the animals of the control group showed severe pulmonary changes post infection, whereas lungs of the cats of the treatment groups were either unaltered (4 animals), mildly (11 animals), or moderately altered (5 animals). Moreover, seroconversion was observed in all cats of the control group, but not in those of the treatment groups. CONCLUSIONS: The combination of diagnostic methods used in this non-terminal study yielded coherent and reliable results. A single administration of Bravecto® Plus spot-on solution for cats was well tolerated and effective in the prevention of aelurostrongylosis for at least 12 weeks.
Asunto(s)
Enfermedades de los Gatos , Heces , Isoxazoles , Macrólidos , Metastrongyloidea , Infecciones por Strongylida , Animales , Gatos , Enfermedades de los Gatos/parasitología , Enfermedades de los Gatos/prevención & control , Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Gatos/diagnóstico , Infecciones por Strongylida/veterinaria , Infecciones por Strongylida/prevención & control , Infecciones por Strongylida/tratamiento farmacológico , Infecciones por Strongylida/diagnóstico , Infecciones por Strongylida/parasitología , Macrólidos/administración & dosificación , Isoxazoles/administración & dosificación , Metastrongyloidea/efectos de los fármacos , Metastrongyloidea/aislamiento & purificación , Heces/parasitología , Masculino , Femenino , Resultado del Tratamiento , Antihelmínticos/administración & dosificación , Larva/efectos de los fármacosRESUMEN
BACKGROUND: The feline lungworm Aelurostrongylus abstrusus affects the lower respiratory tract in cats worldwide. As infections may lead to chronic respiratory changes or even death, preventive treatment in cats with outdoor access is warranted. METHODS: The preventive efficacy of a spot-on solution (Bravecto® Plus spot-on solution for cats, MSD) against cat aelurostrongylosis was evaluated using three different preventive treatment regimes in a negative controlled, randomized and partially blinded laboratory efficacy study with 31 purposed-bred cats. The minimum recommended dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight was applied once 12 (Group [G]1), 8 (G2) or 4 (G3) weeks before experimental infection with 300 third-stage larvae (L3) of A. abstrusus. Another group served as untreated control (G4). Individual faecal samples were analysed as of day 30 post infection (pi) to monitor larvae excretion. Necropsy was performed at days 47-50 pi. The lungs were examined macroscopically for pathological findings and (pre-)adult worms were counted to assess preventive efficacy. RESULTS: Beginning at day 32-40 pi, all cats of the control group were constantly shedding larvae of A. abstrusus, whereas only one animal of G1 excreted larvae at several consecutive days. In addition, two cats of G1 and G3 and three of G2 were positive on a single occasion. The geometric mean (GM) of the maximum number of excreted larvae was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3), resulting in a GM reduction of > 99.9% in all treatment groups. All lungs of the control animals showed severe or very severe alterations at necropsy, while in 94.44% of the treated cats lung pathology was rated as absent or mild. The GM number of (pre-)adult A. abstrusus retrieved from the lungs was 26.57 in the control group, 0.09 in G1 and 0.00 in G2 and G3. Thus, GM worm count reduction was 99.66% in G1 and 100% in G2 and G3. CONCLUSIONS: A single application of Bravecto® Plus spot-on solution at a dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight reliably prevents cat aelurostrongylosis for at least 12 weeks.
Asunto(s)
Antihelmínticos/administración & dosificación , Enfermedades de los Gatos/tratamiento farmacológico , Isoxazoles/administración & dosificación , Macrólidos/administración & dosificación , Metastrongyloidea/efectos de los fármacos , Infecciones por Strongylida/prevención & control , Infecciones por Strongylida/veterinaria , Animales , Enfermedades de los Gatos/parasitología , Enfermedades de los Gatos/patología , Gatos , Femenino , Larva/efectos de los fármacos , Larva/crecimiento & desarrollo , Pulmón/parasitología , Pulmón/patología , Masculino , Metastrongyloidea/crecimiento & desarrollo , Infecciones por Strongylida/parasitología , Infecciones por Strongylida/patología , Resultado del TratamientoRESUMEN
BACKGROUND: The efficacy of the fixed combination of fluralaner plus moxidectin for the treatment of Otodectes cynotis infestations was evaluated in cats after topical application. METHODS: Sixteen cats experimentally infested with O. cynotis were allocated randomly to two groups of 8 cats each. One group was treated topically with the fixed combination of fluralaner plus moxidectin at the minimum dose rate of 40 mg fluralaner and 2 mg moxidectin/kg body weight. The other group was treated with physiological saline solution. Before and 14 and 28 days after treatment the ears of all cats were examined otoscopically for live mites and for the amount of debris and cerumen. Twenty-eight days after treatment, the cats were sedated and had both ears flushed to obtain the total number of live mites per animal. Efficacy was calculated, based on the results of the ear flushing, by comparing mean live mite counts in the fluralaner plus moxidectin treated group versus the saline group. RESULTS: A single topical application of the fixed combination of fluralaner plus moxidectin to cats reduced the mean mite counts by 100% (P < 0.001) by 28 days after treatment. No mites were visible during otoscopic examination at either 14 or 28 days after treatment. All fluralaner plus moxidectin treated cats had less ceruminous exudate 28 days after treatment compared to pre-treatment and 14 days after treatment. No treatment related adverse events were observed in any cats enrolled in the study. CONCLUSIONS: Single topical application of the fixed combination of fluralaner plus moxidectin was highly effective against O. cynotis infestations in cats.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Insecticidas/uso terapéutico , Isoxazoles/uso terapéutico , Macrólidos/uso terapéutico , Infestaciones por Ácaros/veterinaria , Psoroptidae/efectos de los fármacos , Administración Tópica , Animales , Enfermedades de los Gatos/epidemiología , Enfermedades de los Gatos/parasitología , Gatos , Quimioterapia Combinada , Femenino , Insecticidas/administración & dosificación , Isoxazoles/administración & dosificación , Macrólidos/administración & dosificación , Masculino , Infestaciones por Ácaros/tratamiento farmacológico , Infestaciones por Ácaros/epidemiología , Otitis Externa/tratamiento farmacológico , Otitis Externa/parasitología , Otitis Externa/veterinaria , Otoscopía/veterinaria , Soluciones Farmacéuticas/administración & dosificación , Soluciones Farmacéuticas/uso terapéutico , Distribución Aleatoria , Resultado del TratamientoRESUMEN
BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS: To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS: There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS: This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Insecticidas/uso terapéutico , Isoxazoles/uso terapéutico , Macrólidos/uso terapéutico , Nematodos/efectos de los fármacos , Infecciones por Nematodos/veterinaria , Administración Tópica , Animales , Enfermedades de los Gatos/epidemiología , Enfermedades de los Gatos/parasitología , Gatos , Depsipéptidos/administración & dosificación , Depsipéptidos/efectos adversos , Depsipéptidos/uso terapéutico , Europa Oriental/epidemiología , Heces/parasitología , Femenino , Alemania/epidemiología , Insecticidas/administración & dosificación , Insecticidas/efectos adversos , Isoxazoles/administración & dosificación , Isoxazoles/efectos adversos , Macrólidos/administración & dosificación , Macrólidos/efectos adversos , Infecciones por Nematodos/tratamiento farmacológico , Infecciones por Nematodos/epidemiología , Infecciones por Nematodos/parasitología , Recuento de Huevos de Parásitos/veterinaria , Praziquantel/administración & dosificación , Praziquantel/efectos adversos , Praziquantel/uso terapéutico , Distribución Aleatoria , Método Simple Ciego , Siphonaptera/efectos de los fármacos , Siphonaptera/parasitología , Resultado del TratamientoRESUMEN
BACKGROUND: Fluralaner provides efficacy against feline ectoparasites following topical administration. Moxidectin is routinely used to treat gastrointestinal nematode infections and prevent heartworm disease caused by Dirofilaria immitis. Praziquantel is routinely used to treat feline tapeworm infections. The safety of a fluralaner plus moxidectin combination topical solution (Bravecto™ Plus, MSD Animal Health) was assessed when administered concurrently with a commercially available praziquantel topical solution (Droncit™ Spot-on, Bayer Animal Health GmbH). The highest dose rates in clinical use were tested. RESULTS: Concurrent topical administration of a fluralaner plus moxidectin and a praziquantel product did not result in adverse findings. One out of ten cats receiving praziquantel only (control group), and two out of ten cats receiving fluralaner plus moxidectin and praziquantel (treatment group) had dandruff-like flakes in their coat at the application site. Two out of the ten control cats and three cats out of the ten treatment group cats had very small amounts of unidentified material (minute crusts or crumbs) at the application site which was only visible during close inspection. CONCLUSIONS: The concurrent treatment of cats with fluralaner plus moxidectin and praziquantel at the maximum dose in clinical use was well tolerated.
Asunto(s)
Antihelmínticos/administración & dosificación , Enfermedades de los Gatos/tratamiento farmacológico , Insecticidas/administración & dosificación , Isoxazoles/administración & dosificación , Macrólidos/administración & dosificación , Praziquantel/administración & dosificación , Acaricidas/administración & dosificación , Acaricidas/efectos adversos , Administración Tópica , Animales , Antihelmínticos/efectos adversos , Antihelmínticos/uso terapéutico , Enfermedades de los Gatos/parasitología , Enfermedades de los Gatos/prevención & control , Gatos , Dirofilariasis/tratamiento farmacológico , Dirofilariasis/prevención & control , Quimioterapia Combinada/métodos , Quimioterapia Combinada/estadística & datos numéricos , Quimioterapia Combinada/veterinaria , Infestaciones Ectoparasitarias/tratamiento farmacológico , Infestaciones Ectoparasitarias/prevención & control , Infestaciones Ectoparasitarias/veterinaria , Femenino , Insecticidas/efectos adversos , Insecticidas/uso terapéutico , Isoxazoles/efectos adversos , Isoxazoles/uso terapéutico , Macrólidos/efectos adversos , Macrólidos/uso terapéutico , Masculino , Infecciones por Nematodos/tratamiento farmacológico , Infecciones por Nematodos/prevención & control , Praziquantel/efectos adversos , Praziquantel/uso terapéutico , Distribución Aleatoria , Resultado del TratamientoRESUMEN
BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. METHODS: Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment. RESULTS: In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated. CONCLUSIONS: A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Infestaciones por Pulgas/veterinaria , Insecticidas/uso terapéutico , Isoxazoles/uso terapéutico , Macrólidos/uso terapéutico , Infestaciones por Garrapatas/veterinaria , Administración Tópica , Animales , Enfermedades de los Gatos/epidemiología , Enfermedades de los Gatos/parasitología , Gatos , Infestaciones por Pulgas/tratamiento farmacológico , Infestaciones por Pulgas/epidemiología , Alemania/epidemiología , Insecticidas/administración & dosificación , Insecticidas/efectos adversos , Isoxazoles/administración & dosificación , Isoxazoles/efectos adversos , Ixodes/efectos de los fármacos , Macrólidos/administración & dosificación , Macrólidos/efectos adversos , Propiedad , Pirazoles/administración & dosificación , Pirazoles/uso terapéutico , Distribución Aleatoria , Rhipicephalus sanguineus/efectos de los fármacos , Método Simple Ciego , España/epidemiología , Infestaciones por Garrapatas/tratamiento farmacológico , Infestaciones por Garrapatas/epidemiología , Resultado del TratamientoRESUMEN
BACKGROUND: The efficacy of fluralaner for the treatment of Otodectes cynotis infestations in dogs and cats was evaluated after oral (dogs) or topical administration (dogs and cats). Twenty-four dogs and sixteen cats were experimentally infested with O. cynotis and randomly allocated to equal sized groups (n = 8/group). Dog groups were treated once, either orally with fluralaner at a minimum dose of 25 mg/kg body weight, topically with fluralaner at a dose of 25 mg/kg body weight or topically with saline solution (control). Cat groups were treated once, either topically with fluralaner at a dose of 40 mg/kg body weight or topically with saline solution. Ears of all animals were examined otoscopically for live visible mites and the amount of debris and cerumen before, and 14 and 28 days after treatment. Twenty-eight days after treatment, animals were sedated and both ears were flushed to obtain the total number of live mites per animal. The efficacy was calculated, based on the results of the ear flushing, by comparing mean live mite counts in the fluralaner treated groups versus the saline solution treated group. RESULTS: A single topical treatment of cats with fluralaner reduced the mean mite counts by 100% (P < 0.001) at 28 days after treatment. Similarly, a single oral or topical treatment of dogs with fluralaner reduced the mean mite counts by 99.8% (P < 0.001) at 28 days after treatment. Cats treated topically with fluralaner had no mites visible during otoscopic examination at either 14 or 28 days after treatment. All dogs treated orally or topically with fluralaner had no mites visible during otoscopic examination at 28 days after treatment. At 14 days after treatment, only 1-2 mites were visible in three dogs (oral treatment: 2 dogs, topical treatment: 1 dog). All fluralaner-treated animals showed improvement in the amount of cerumen exudation compared with observations performed before treatment. No treatment related adverse events were observed in any dogs or cats enrolled in these studies. CONCLUSIONS: In this study, fluralaner administered topically to cats and orally or topically to dogs was highly effective against Otodectes cynotis mite infestations.
Asunto(s)
Acaricidas/administración & dosificación , Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Perros/tratamiento farmacológico , Isoxazoles/administración & dosificación , Infestaciones por Ácaros/veterinaria , Psoroptidae/efectos de los fármacos , Administración Tópica , Animales , Enfermedades de los Gatos/parasitología , Gatos , Enfermedades de los Perros/parasitología , Perros , Femenino , Masculino , Infestaciones por Ácaros/tratamiento farmacológico , Infestaciones por Ácaros/parasitología , Psoroptidae/fisiologíaRESUMEN
BACKGROUND: The efficacy of fluralaner, formulated as a chewable tablet (Bravecto™) or topical solution (Bravecto™ Spot-on Solution), was evaluated against naturally acquired Sarcoptes scabiei var. canis infestation in dogs. METHODS: The study was performed in privately-owned dogs naturally infested with S. scabiei var. canis. All dogs living in the same household as the infested dog were enrolled into one of 3 groups (2 fluralaner treated and 1 negative control). All dogs within one household were administered the same treatment, with one dog per household included in further observations and assessments. In total, 29 dogs confirmed positive for sarcoptic mange were included. On Day 0, all dogs in group 1 (n = 9) were treated once orally with fluralaner at a minimum dose of 25 mg/kg body weight; all dogs in group 2 (n = 11) were treated once topically with fluralaner at a dose of 25 mg/kg body weight; and dogs in group 3 (n = 9) were treated once topically with saline solution. Sarcoptes scabiei var. canis mites on each dog were counted before treatment and at 4 weeks after treatment in deep skin scrapings (~4 cm(2)) from 5 different body areas. Clinical signs of infestation (i.e. erythematous papules; casts, scales and crusts; body areas with hair loss) and pruritus were recorded at the same time points. RESULTS: Single oral or topical treatment with fluralaner resulted in a 100 % reduction in mite counts post-treatment (group 1: P = 0.0009 and group 2: P = 0.0011). Resolution of clinical signs at four weeks post-treatment was variable, with improvement observed for erythematous papules, casts and crusts, and pruritus. All fluralaner treated dogs showed an improvement in overall hair re-growth compared with pre-treatment observations. CONCLUSION: Fluralaner administered either orally or topically to naturally infested dogs eliminates Sarcoptes scabiei var. canis mites and improves clinical signs over a 4-week observation period.
Asunto(s)
Acaricidas/administración & dosificación , Enfermedades de los Perros/tratamiento farmacológico , Isoxazoles/administración & dosificación , Sarcoptes scabiei/efectos de los fármacos , Escabiosis/veterinaria , Administración Oral , Administración Tópica , Animales , Enfermedades de los Perros/parasitología , Perros , Femenino , Masculino , Escabiosis/tratamiento farmacológico , ComprimidosRESUMEN
BACKGROUND: Fluralaner spot-on solution provides immediate and persistent efficacy against tick and flea infestations in dogs and cats for 12-weeks following topical administration. The active ingredient fluralaner is distributed systemically following transdermal absorption. Therefore, this study tested the hypothesis whether water-immersion or shampooing of dogs following administration of fluralaner spot-on solution has an impact on subsequent tick and flea efficacy. METHODS: Thirty-two Beagle dogs were allocated to four study groups of 8 dogs each. On day 0, dogs in the 2 treatment groups received topical administration of fluralaner (Bravecto™ spot-on solution) according to label instructions. Dogs in the 2 corresponding control groups remained untreated. On days 3, 21, 49, and 77 dogs in one treatment group and control group were water-immersed for 2-5 min, while dogs in the other treatment group and control group were shampooed 6-8 min with a commercial foaming micro-emulsion, unscented product. On days 4, 28, 56, and 84 all dogs were co-infested with 50 ± 2 female and 10 ± 2 male Ixodes ricinus and 100 ± 4 Ctenocephalides felis, with tick and flea removal and counts 48 ± 2 h post-infestation. Efficacy against ticks and fleas was calculated for each assessment time point. RESULTS: No treatment-related adverse event was observed in any of the 16 dogs treated with fluralaner spot-on solution during the study. Efficacy against ticks at each assessment time point was between 99.7 and 100 % in the water-immersed group and between 99.2 and 100 % in the shampooed group. Efficacy against fleas was 100 % at each assessment time point as well in the water-immersed as the shampooed group. Tick and flea reduction in both treatment groups was significant at all assessment time points (p < 0.0001). CONCLUSIONS: Neither water-immersion nor shampooing after single topical administration of fluralaner spot-on solution had an impact on the excellent tick and flea efficacy over the 12-week recommended re-treatment interval.
Asunto(s)
Ctenocephalides/efectos de los fármacos , Enfermedades de los Perros/prevención & control , Infestaciones por Pulgas/veterinaria , Insecticidas/administración & dosificación , Ixodes/efectos de los fármacos , Infestaciones por Garrapatas/veterinaria , Acaricidas/administración & dosificación , Administración Tópica , Animales , Baños/efectos adversos , Enfermedades de los Perros/parasitología , Perros , Femenino , Infestaciones por Pulgas/prevención & control , Isoxazoles/administración & dosificación , Masculino , Soluciones Farmacéuticas , Absorción Cutánea , Jabones/efectos adversos , Infestaciones por Garrapatas/prevención & control , Resultado del Tratamiento , Agua/efectos adversosRESUMEN
BACKGROUND: The preventive effect of fluralaner spot-on solution against transmission of Babesia canis by Dermacentor reticulatus ticks was evaluated. FINDINGS: Sixteen dogs, tested negative for B. canis by polymerase chain reaction (PCR) and immunofluorescence assay test (IFAT), were allocated to two study groups. On day 0, dogs in one group (n = 8) were treated once topically with fluralaner spot-on solution (Bravecto™ Spot-on Solution) according to label recommendations and dogs in the control group (n = 8) remained untreated. On days 2, 28, 56, 70 and 84, all dogs were infested with 50 (±4) D. reticulatus ticks harbouring B. canis, with tick in situ thumb counts 48 ± 4 h after each infestation. On day 90, ticks were removed from all dogs and counted. Prior to each infestation, the presence of B. canis in the respective tick batch was confirmed by PCR, and 12-16 % of ticks were found to be infected with B. canis. Efficacy against ticks was 99.5 and 99.3 % on days 4 and 58 after treatment, respectively and 100 % on all other days. Replacement dogs were included for any B. canis infected control dog (in total 19). All control dogs (n = 27) became infected with B. canis, as confirmed by PCR, performed every 7 days, and by IFAT, performed every 14 days after treatment. None of the eight treated dogs became infected with B. canis, as they were tested negative by PCR and IFAT throughout the study until day 112. By comparing infected dogs in the treated group with infected dogs in the untreated control group, a 100 % preventive effect against B. canis transmission was demonstrated. CONCLUSIONS: A single topical administration of fluralaner spot-on solution effectively prevented the transmission of B. canis by infected D. reticulatus ticks over a 12-week period.
Asunto(s)
Acaricidas/administración & dosificación , Vectores Arácnidos/efectos de los fármacos , Babesiosis/transmisión , Dermacentor/efectos de los fármacos , Enfermedades de los Perros/prevención & control , Infestaciones por Garrapatas/veterinaria , Administración Tópica , Animales , Vectores Arácnidos/parasitología , Babesia/fisiología , Babesiosis/parasitología , Dermacentor/parasitología , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/transmisión , Perros , Femenino , Isoxazoles/administración & dosificación , Masculino , Soluciones Farmacéuticas , Infestaciones por Garrapatas/prevención & control , Resultado del TratamientoRESUMEN
BACKGROUND: The efficacy of fluralaner spot-on solution administered once topically against induced infestations with Rhipicephalus sanguineus was evaluated in dogs over a 12-week post-treatment period. METHODS: Six negative-controlled studies were conducted, involving a total of 112 adult dogs (57 mixed breed, 47 Beagles, eight Labradors). In each study, dogs were randomized to two groups of eight to ten dogs each. On day 0, dogs in each treated group were topically administered fluralaner spot-on solution once at a dose of 25 mg/kg body weight, while dogs in each control group were not treated. Two days before treatment, and on days 28, 56 and 84 after treatment, all dogs were infested with approximately 50 unfed, adult Rh. sanguineus ticks (sex ratio 1:1). Ticks were removed and counted on days 2, 30 (4 weeks), 58 (8 weeks), and 86 (12 weeks) after treatment to assess efficacy. RESULTS: Efficacy against ticks 2 days after treatment was 91.1 % (study 1), 98.4 % (study 2), 100 % (study 3), 97.6 % (study 4), 99.6 % (study 5), and 99.8 % (study 6). At all other assessment time points, tick efficacy was 95.4-100 %. Tick reduction in all treatment groups was significant at all assessment time points (P < 0.0001). CONCLUSIONS: A single topical administration of fluralaner spot-on solution provides a high level of therapeutic and persistent efficacy against Rh. sanguineus ticks over the subsequent 12 weeks.
Asunto(s)
Acaricidas/administración & dosificación , Vectores Arácnidos/efectos de los fármacos , Enfermedades de los Perros/prevención & control , Isoxazoles/administración & dosificación , Rhipicephalus sanguineus/efectos de los fármacos , Infestaciones por Garrapatas/veterinaria , Administración Tópica , Animales , Vectores Arácnidos/parasitología , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/transmisión , Perros , Femenino , Masculino , Soluciones Farmacéuticas , Rhipicephalus sanguineus/parasitología , Infestaciones por Garrapatas/prevención & control , Resultado del TratamientoRESUMEN
BACKGROUND: Fluralaner is a novel systemic ectoparasiticide for cats providing immediate and persistent flea- and tick-control after a single topical dose. Emodepsid and praziquantel are routinely used to control intestinal worm infections in cats. The safety of concurrent use of fluralaner and a commercially available emodepsid-praziquantel combination topical solution was investigated using topical administrations at the maximum recommended dose rates. FINDINGS: Few mild and transient clinical findings like erythema at the administration site and single incidences of salivation or vomiting were observed. All of which were consistent with the individual product leaflets. There were no findings suggesting an increased safety risk associated with the concurrent treatment of cats with fluralaner and emodepsid-praziquantel. CONCLUSIONS: Concurrent treatment with fluralaner, emodepsid and praziquantel is well tolerated in cats.
Asunto(s)
Antihelmínticos/efectos adversos , Enfermedades de los Gatos/tratamiento farmacológico , Depsipéptidos/efectos adversos , Insecticidas/efectos adversos , Isoxazoles/efectos adversos , Praziquantel/efectos adversos , Animales , Antihelmínticos/administración & dosificación , Antihelmínticos/farmacocinética , Enfermedades de los Gatos/parasitología , Gatos , Depsipéptidos/administración & dosificación , Depsipéptidos/farmacocinética , Dermatitis por Contacto/veterinaria , Interacciones Farmacológicas , Quimioterapia Combinada , Infestaciones Ectoparasitarias/tratamiento farmacológico , Infestaciones Ectoparasitarias/veterinaria , Eritema/inducido químicamente , Eritema/veterinaria , Femenino , Insecticidas/administración & dosificación , Insecticidas/farmacocinética , Parasitosis Intestinales/tratamiento farmacológico , Parasitosis Intestinales/veterinaria , Isoxazoles/administración & dosificación , Isoxazoles/farmacocinética , Masculino , Praziquantel/administración & dosificación , Praziquantel/farmacocinética , Salivación/efectos de los fármacosRESUMEN
BACKGROUND: Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting the p-glycoprotein transporter, potentially increasing the risk of ivermectin neurotoxicity. This study investigated ivermectin blood plasma pharmacokinetics following concurrent administration with fluralaner. FINDINGS: Ten Beagle dogs each received a single oral administration of either 56 mg fluralaner (Bravecto™), 0.3 mg ivermectin or 56 mg fluralaner plus 0.3 mg ivermectin/kg body weight. Blood plasma samples were collected at multiple post-treatment time points over a 12-week period for fluralaner and ivermectin plasma concentration analysis. Ivermectin blood plasma concentration profile and pharmacokinetic parameters Cmax, tmax, AUC∞ and t½ were similar in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner, and the same was true for fluralaner pharmacokinetic parameters. CONCLUSIONS: Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either compound. Based on the plasma pharmacokinetic profile and the clinical observations, there is no evident interaction between fluralaner and ivermectin, and co-administration does not increase the risk of ivermectin associated neurotoxicity.
Asunto(s)
Perros/sangre , Insecticidas/farmacocinética , Isoxazoles/farmacocinética , Ivermectina/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Interacciones Farmacológicas , Semivida , Insecticidas/administración & dosificación , Insecticidas/sangre , Isoxazoles/administración & dosificación , Isoxazoles/sangre , Ivermectina/administración & dosificación , Ivermectina/sangreRESUMEN
BACKGROUND: Fluralaner is a new antiparasitic drug that was recently introduced as Bravecto chewable tablets for the treatment of tick and flea infestations in dogs. Most marketed tick products exert their effect via topical application and contact exposure to the parasite. In contrast, Bravecto delivers its acaricidal activity through systemic exposure. Tick exposure to fluralaner occurs after attachment to orally treated dogs, which induces a tick-killing effect within 12 h. The fast onset of killing lasts over the entire treatment interval (12 weeks) and suggests that only marginal uptake by ticks is required to induce efficacy. Three laboratory studies were conducted to quantify the extent of uptake by comparison of ticks' weight and coxal index obtained from Bravecto-treated and negative-control dogs. METHODS: Three studies were conducted using experimental tick infestation with either Ixodes ricinus or Ixodes scapularis after oral administration of fluralaner to dogs. All studies included a treated (Bravecto chewable tablets, MSD Animal Health) and a negative control group. Each study had a similar design for assessing vitality and weighing of ticks collected from dogs of both groups. Additionally, in one study the coxal index (I. ricinus) was calculated as a ratio of tick's ventral coxal gap and dorsal width of scutum. Tick weight data and coxal indices from Bravecto-treated and negative-control groups were compared via statistical analysis. RESULTS: Ticks collected from Bravecto-treated dogs weighed significantly less (p ≤ 0.0108) than ticks collected from negative-control dogs, and their coxal index was also significantly lower (p < 0.0001). The difference in tick weights was demonstrated irrespective of the tick species investigated (I. ricinus, I. scapularis). At some assessments the mean tick weights of Bravecto-treated dogs were significantly lower than those of unfed pre-infestation (baseline) ticks. The demonstrated tick-killing efficacy was in the range of 94.6 - 100%. CONCLUSIONS: Tick weights and coxal indices confirm that a minimal uptake results in a sufficient exposure of ticks to fluralaner (Bravecto) and consequently in a potent acaricidal effect.
Asunto(s)
Acaricidas/administración & dosificación , Enfermedades de los Perros/tratamiento farmacológico , Isoxazoles/administración & dosificación , Ixodes/efectos de los fármacos , Infestaciones por Garrapatas/veterinaria , Animales , Peso Corporal/efectos de los fármacos , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/fisiopatología , Perros , Evaluación de Medicamentos/veterinaria , Femenino , Ixodes/crecimiento & desarrollo , Ixodes/fisiología , Masculino , Infestaciones por Garrapatas/tratamiento farmacológico , Infestaciones por Garrapatas/parasitología , Infestaciones por Garrapatas/fisiopatologíaRESUMEN
BACKGROUND: The preventive effect of fluralaner chewable tablets (Bravecto™) against transmission of Babesia canis by Dermacentor reticulatus ticks was evaluated. METHODS: Sixteen dogs, tested negative for B. canis by PCR and IFAT, were allocated to two study groups. On day 0, dogs in one group (n = 8) were treated once orally with a fluralaner chewable tablet according to label recommendations and dogs in the control group (n = 8) remained untreated. On days 2, 28, 56, 70 and 84, dogs were infested with 50 (±4) B. canis infected D. reticulatus ticks with tick in situ thumb counts 48 ± 4 h post-infestation. Prior to each infestation, the D. reticulatus ticks were confirmed to harbour B. canis by PCR analysis. On day 90, ticks were counted and removed from all dogs. Efficacy against ticks was calculated for each assessment time point. After treatment, all dogs were physically examined in conjunction with blood collection for PCR every 7 days, blood samples for IFAT were collected every 14 days and the dog's rectal body temperature was measured thrice weekly. From dogs displaying symptoms of babesiosis or were PCR positive, a blood smear was taken, and, if positive, dogs were rescue treated and replaced with a replacement dog. The preventive effect was evaluated by comparing infected dogs in the treated group with infected dogs in the untreated control group. RESULTS: All control dogs became infected with B. canis, as confirmed by PCR and IFAT. None of the 8 treated dogs became infected with B. canis, as IFAT and PCR were negative throughout the study until day 112. Fluralaner chewable tablet was 100 % effective against ticks on days 4, 30, 58, and 90 and an efficacy of 99.6 % and 99.2 % was achieved on day 72 and day 86 after treatment, respectively. Over the 12-week study duration, a 100 % preventive effect against B. canis transmission was demonstrated. CONCLUSIONS: A single oral administration of fluralaner chewable tablets effectively prevented the transmission of B. canis by infected D. reticulatus ticks over a 12-week period.
Asunto(s)
Vectores Arácnidos/efectos de los fármacos , Babesia/fisiología , Babesiosis/prevención & control , Dermacentor/efectos de los fármacos , Enfermedades de los Perros/prevención & control , Isoxazoles/farmacología , Infestaciones por Garrapatas/veterinaria , Administración Oral , Animales , Vectores Arácnidos/parasitología , Babesiosis/transmisión , Dermacentor/parasitología , Enfermedades de los Perros/transmisión , Perros , Femenino , Masculino , Comprimidos , Infestaciones por Garrapatas/tratamiento farmacológicoRESUMEN
BACKGROUND: Fluralaner is a novel isoxazoline eliciting both acaricidal and insecticidal activity through potent blockage of GABA- and glutamate-gated chloride channels. The aim of the study was to investigate the susceptibility of juvenile stages of common tick species exposed to fluralaner through either contact (Rhipicephalus sanguineus) or contact and feeding routes (Ornithodoros moubata). METHODS: Fluralaner acaricidal activity through both contact and feeding exposure was measured in vitro using two separate testing protocols. Acaricidal contact activity against Rhipicephalus sanguineus life stages was assessed using three minute immersion in fluralaner concentrations between 50 and 0.05 µg/mL (larvae) or between 1000 and 0.2 µg/mL (nymphs and adults). Contact and feeding activity against Ornithodoros moubata nymphs was assessed using fluralaner concentrations between 1000 to 10(-4) µg/mL (contact test) and 0.1 to 10(-10) µg/mL (feeding test). Activity was assessed 48 hours after exposure and all tests included vehicle and untreated negative control groups. RESULTS: Fluralaner lethal concentrations (LC50, LC90/95) were defined as concentrations with either 50%, 90% or 95% killing effect in the tested sample population. After contact exposure of R. sanguineus life stages lethal concentrations were (µg/mL): larvae - LC50 0.7, LC90 2.4; nymphs - LC50 1.4, LC90 2.6; and adults - LC50 278, LC90 1973. After exposure of O. moubata nymphs to fluralaner lethal concentrations were (µg/mL): contact exposure - LC50 720, LC95 1133; and feeding exposure- LC50 0.00007, LC95 0.09. CONCLUSIONS: Fluralaner demonstrates potent in vitro acaricidal activity against all life stages of the brown dog tick, R.sanguineus. The testing of fluralaner contact and feeding routes using O. moubata nymphs demonstrates a high acaricidal activity in both exposure routes.
Asunto(s)
Acaricidas/toxicidad , Enfermedades de los Perros/parasitología , Isoxazoles/toxicidad , Ornithodoros/efectos de los fármacos , Rhipicephalus sanguineus/efectos de los fármacos , Rhipicephalus sanguineus/crecimiento & desarrollo , Infestaciones por Garrapatas/veterinaria , Animales , Perros , Conducta Alimentaria/efectos de los fármacos , Femenino , Masculino , Ornithodoros/crecimiento & desarrollo , Ornithodoros/fisiología , Rhipicephalus sanguineus/fisiología , Infestaciones por Garrapatas/parasitologíaRESUMEN
BACKGROUND: Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. METHODS: Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1 study) and the speed of flea kill (2 studies) of fluralaner. All dogs were infested prior to treatment with unfed adult C. felis fleas. Dogs in the treated groups were administered once orally with fluralaner at a minimum dose of 25 mg/kg body weight, while dogs in the control groups were not treated. Separate control and treatment groups were paired at each time point of flea assessment. Flea counts were performed by combing dogs at either 0.5, 1, 2, or 4 hours after fluralaner treatment to measure the start to kill. To evaluate the speed of flea kill over 12 weeks, flea counts were performed by combing dogs at either 4, 8, 12, or 24 hours after fluralaner treatment and then at 4, 8, 12, or 24 hours after each flea re-infestations performed at 4, 8, and 12 weeks following treatment. RESULTS: In the start to kill study, the fluralaner activity against fleas started already at 1 hour post-treatment (8% numerical efficacy). At 2 and 4 hours post-treatment, the flea reduction was significant with 36.7% and 88% efficacy, respectively. In the speed of kill studies, the efficacy against fleas after fluralaner treatment was 80.5% at 4 hours and remained ≥ 99.4% at 8, 12 and 24 hours. After flea re-infestations in weeks 4, 8 and 12, the efficacy at 4 hours was 96.8, 91.4, and 33.5%, respectively. Efficacy at 8, 12 and 24 hours after flea re-infestations was 98.0-100% for the 12 weeks of the study. Except for 4 hours after the 12-week flea re-infestation, flea reduction was significant for all time points after flea re-infestation. CONCLUSIONS: Single oral fluralaner administration rapidly eliminates existing flea infestations and provides excellent protection against fleas over 12 weeks following treatment.
Asunto(s)
Enfermedades de los Perros/tratamiento farmacológico , Infestaciones por Pulgas/veterinaria , Insecticidas/uso terapéutico , Isoxazoles/uso terapéutico , Administración Oral , Animales , Perros , Femenino , Infestaciones por Pulgas/tratamiento farmacológico , Insecticidas/administración & dosificación , Isoxazoles/administración & dosificación , MasculinoRESUMEN
BACKGROUND: Pathogens that are transmitted by ticks to dogs, such as Anaplasma phagocytophilum, Babesia spp., Borrelia burgdorferi sensu latu, and Ehrlichia canis, are an increasing problem in the world. One method to prevent pathogen transmission to dogs is to kill the ticks before transmission occurs. Fluralaner (Bravecto™) is a novel isoxazoline insecticide and acaricide that provides long persistent antiparasitic activity following systemic administration. This study investigated the speed of kill of fluralaner against Ixodes ricinus ticks on dogs. METHODS: A total of 48 dogs were randomized to 8 groups of 6 dogs and each dog was infested with 50 female and 10 male I. ricinus ticks. Two days later (day 0), 4 groups received a single treatment of 25 mg fluralaner/kg body weight as Bravecto™ chewable tablets; the dogs in the other 4 groups were left untreated. Separate control and treatment groups were paired at each time point (4, 8, 12, or 24 hours after treatment) for assessment of tick-killing efficacy. At 4, 8, and 12 weeks after treatment, all dogs were re-infested with 50 female I. ricinus ticks and subsequently assessed for live or dead ticks at either 4, 8, 12, or 24 hours after re-infestation. Efficacy was calculated for each assessment time point by comparison of the treatment group with the respective control group. RESULTS: Tick-killing efficacy was 89.6% at 4 hours, 97.9% at 8 hours, and 100% at 12 and 24 hours after treatment. Eight hours after re-infestation, efficacy was 96.8%, 83.5%, and 45.8% at 4, 8, and 12 weeks after treatment, respectively. At least 98.1% tick-killing efficacy was demonstrated 12 and 24 hours after re-infestation over the entire 12 week study period. CONCLUSIONS: Fluralaner kills ticks rapidly after treatment at 4 hours, and over its entire 12-week period of efficacy, it achieves an almost complete killing effect within 12 hours after tick infestation. The rapid tick-killing effect together with the long duration of efficacy enables fluralaner to aid in the prevention of tick borne diseases.
Asunto(s)
Acaricidas/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Isoxazoles/uso terapéutico , Ixodes/efectos de los fármacos , Infestaciones por Garrapatas/tratamiento farmacológico , Animales , Enfermedades de los Perros/parasitología , Perros , Femenino , Masculino , Factores de TiempoRESUMEN
BACKGROUND: Fluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing long-acting flea and tick control after a single oral dose. Milbemycin oxime and praziquantel are routinely used to control Dirofilaria immitis and intestinal worm infections in dogs. The safety of concurrent use of fluralaner and a commercially available milbemycin oxime plus praziquantel combination tablet, in particular with regard to gastrointestinal symptoms, was investigated using oral doses at or above the maximum recommended rates. FINDINGS: Some minor and transient clinical findings were observed during the study period; however, none of these was considered to be related to concurrent treatment with fluralaner and milbemycin oxime plus praziquantel, or to the use of either product alone. CONCLUSIONS: Concurrent treatment with fluralaner, milbemycin oxime and praziquantel is well tolerated in dogs.